<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms

Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor and indire...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Guo Ge, Lyndsey Bolanos, Mark Wunderlich, Johann-Christoph Jann, Alina Wein, Eva Altrock, Marie Demmerle, Sanjay Mukherjee, Abdullah Mahmood Ali, Felicitas Rapp, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Melda Göl, Ahmed Jawhar, Ali Darwich, Patrick Wuchter, Christel Weiss, Azra Raza, Jason M. Foulks, Daniel T. Starczynowski, Feng-Chun Yang, Georgia Metzgeroth, Laurenz Steiner, Mohamad Jawhar, Wolf-Karsten Hofmann, Daniel Nowak
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2023-11-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/11329
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!